Workflow
IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
IQVIAIQVIA(US:IQV) ZACKSยท2025-05-01 14:21

Core Insights - Wall Street analysts anticipate IQVIA Holdings (IQV) to report quarterly earnings of $2.63 per share, reflecting a year-over-year increase of 3.5% [1] - Expected revenues for the quarter are projected at $3.77 billion, which represents a 0.9% increase from the previous year [1] Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 0.1%, indicating a collective reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - Analysts estimate 'Revenues- Technology & Analytics Solutions' to be $1.52 billion, indicating a year-over-year increase of 4.4% [5] - The consensus for 'Revenues- Research & Development Solution' is projected at $2.08 billion, suggesting a decline of 0.9% year over year [5] - 'Revenues- Contract Sales & Medical Solutions' is expected to reach $183.42 million, reflecting a year-over-year decrease of 3% [5] Segment Profit Estimates - The estimated 'Backlog' for IQVIA is $31.43 billion, up from $30.1 billion in the same quarter last year [6] - Analysts project 'Segment Profit- Technology & Analytics Solution' to be $365.56 million, an increase from $335 million reported in the same quarter last year [6] - 'Segment Profit- Contract Sales & Medical Solutions' is expected to be $15.65 million, compared to $13 million in the same quarter last year [7] - The average prediction for 'Segment Profit- Research & Development Solutions' is $471.69 million, slightly down from $479 million reported in the same quarter last year [7] Stock Performance - IQVIA shares have decreased by 11.1% over the past month, contrasting with a decline of 0.7% in the Zacks S&P 500 composite [7] - With a Zacks Rank of 4 (Sell), IQV is expected to underperform the overall market in the near term [7]